CRISPR's first potential approval races a live clinical hold: lonvo-z's March 2027 PDUFA defines the bull case while nex-z's safety resolution remains open

Intellia is a clinical-stage biotechnology company developing CRISPR gene-editing therapies, with its lead program lonvo-z not yet approved but facing an FDA decision in March 2027 for the treatment of hereditary angioedema, a rare blood disorder causing severe swelling attacks.

Intellia holds the first CRISPR therapy on the cusp of FDA approval, with lonvo-z delivering an 87% HAE attack reduction and a clean safety profile in Phase 3. Whether the thesis works hinges on FDA approving lonvo-z at the March 2027 PDUFA date, without advisory committee review, while nex-z's hold resolves without permanent program damage. The primary risk is that nex-z's HLA-associated liver toxicity, which caused one patient death, proves broader than the identified genetic subset, stranding Intellia's larger ATTR opportunity.